{
  "id": 10403733,
  "title": "Eli Lilly Just Announced Game-Changing News",
  "url": "https://urgent.news/2026/09/28/eli-lilly-just-announced-game-changing-news",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-28T08:03:01.000Z",
  "source": {
    "name": "Motley Fool",
    "slug": "motley-fool",
    "url": "https://www.fool.com/investing/2026/09/28/eli-lilly-just-announced-game-changing-news/?source=iedfolrf0000001"
  },
  "original_language": "en",
  "account": "Eli Lilly has announced groundbreaking developments in the weight loss drug market. The pharmaceutical giant, known for its diverse portfolio of treatments, has seen significant earnings growth thanks to a specific drug category. This market is projected to reach nearly $100 billion by 2030, and the focus is on weight loss drugs, especially those within the GLP-1 category. Lilly's tirzepatide, sold as Mounjaro for type 2 diabetes and Zepbound for weight loss, are injectable medications. The company has also received approval for its first oral weight loss drug, Foundayo. However, Lilly faces competition from Novo Nordisk, the original market leader with Ozempic and Wegovy. As Medicare coverage expands and oral weight loss drugs gain traction, both companies are striving to lead in this emerging market.",
  "summary": "Something new is happening in the weight loss drug market.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Nasdaq Markets",
        "title": "Eli Lilly Just Announced Game-Changing News",
        "url": "https://urgent.news/2026/09/28/eli-lilly-just-announced-game-changing-news-10404807",
        "published": "2026-09-28T08:23:01.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}